These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19180893)

  • 1. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses.
    Resnick L; Rabinovitz H; Binninger D; Marchetti M; Weissbach H
    J Drugs Dermatol; 2009 Jan; 8(1):29-32. PubMed ID: 19180893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
    Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
    Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
    Dirschka T; Bierhoff E; Pflugfelder A; Garbe C
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):258-63. PubMed ID: 19709346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases.
    Ulrich C; Hackethal M; Ulrich M; Howorka A; Forschner T; Sterry W; Stockfleth E
    Br J Dermatol; 2007 May; 156 Suppl 3():40-2. PubMed ID: 17488405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
    Criscione VD; Weinstock MA; Naylor MF; Luque C; Eide MJ; Bingham SF;
    Cancer; 2009 Jun; 115(11):2523-30. PubMed ID: 19382202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
    Minami T; Adachi M; Kawamura R; Zhang Y; Shinomura Y; Imai K
    Clin Cancer Res; 2005 Jul; 11(14):5248-56. PubMed ID: 16033843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
    Rivers JK; McLean DI
    Arch Dermatol; 1997 Oct; 133(10):1239-42. PubMed ID: 9382562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses.
    Mastrolonardo M
    Clin Exp Dermatol; 2009 Jan; 34(1):33-5. PubMed ID: 18616726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin.
    Butler GJ; Neale R; Green AC; Pandeya N; Whiteman DC
    J Am Acad Dermatol; 2005 Dec; 53(6):966-72. PubMed ID: 16310056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
    Rivers JK
    Skin Therapy Lett; 2004 Jan; 9(1):1-3. PubMed ID: 14716439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical findings using ingenol mebutate gel to treat actinic keratoses.
    Martin G; Swanson N
    J Am Acad Dermatol; 2013 Jan; 68(1 Suppl 1):S39-48. PubMed ID: 23228305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of actinic keratoses.
    Shoimer I; Rosen N; Muhn C
    Skin Therapy Lett; 2010 May; 15(5):5-7. PubMed ID: 20505896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.
    Campione E; Diluvio L; Paternò EJ; Chimenti S
    Am J Clin Dermatol; 2010; 11(1):45-50. PubMed ID: 20000874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and emerging topical approaches for actinic keratoses.
    Del Rosso JQ
    Cutis; 2003 Oct; 72(4):273-6, 279. PubMed ID: 14604078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
    Stockfleth E
    J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study.
    Huyke C; Reuter J; Rödig M; Kersten A; Laszczyk M; Scheffler A; Nashan D; Schempp C
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):128-33. PubMed ID: 18808378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids.
    Tutrone WD; Saini R; Caglar S; Weinberg JM; Crespo J
    Cutis; 2003 May; 71(5):373-9. PubMed ID: 12769404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical management of actinic keratosis and field cancerisation.
    Stockfleth E
    G Ital Dermatol Venereol; 2009 Aug; 144(4):459-62. PubMed ID: 19755950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actinic keratoses: non-invasive diagnosis for field cancerisation.
    Ulrich M; Maltusch A; Röwert-Huber J; González S; Sterry W; Stockfleth E; Astner S
    Br J Dermatol; 2007 May; 156 Suppl 3():13-7. PubMed ID: 17488401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.